Tags

Type your tag names separated by a space and hit enter

Comparison of efficacy and health-related quality of life of first-line haploidentical hematopoietic stem cell transplantation with unrelated cord blood infusion and first-line immunosuppressive therapy for acquired severe aplastic anemia.
Leukemia. 2020 Jun 26 [Online ahead of print]L

Abstract

We retrospectively compared the efficacy and health-related quality of life (HRQoL) of (1) first-line haploidentical hematopoietic stem cell transplantation (haplo-HSCT, n = 146) combined with unrelated cord blood (UCB) infusion and (2) first-line immunosuppressive therapy (IST, n = 219) in acquired severe aplastic anemia (SAA) patients. At 6 months post treatment, 90.30% patients in the haplo-HSCT group and 18.78% patients in the IST group achieved normal blood routine (P < 0.0001). The time required to discontinue red blood cells and platelets transfusion in the IST group were longer than in the haplo-HSCT group (P < 0.0001). The estimated overall survival at 4 years was similar (80.1 ± 3.5% vs. 80.1 ± 3.0%, P = 0.726); the estimated failure-free survival (FFS) at 4 years was 77.8 ± 3.7% in the haplo-HSCT group and 48.0 ± 3.6% in the IST group (P < 0.0001). Patients treated with haplo-HSCT scored significantly better in the HRQoL than treated with IST (P < 0.0001). In the multivariate analysis, first-line haplo-HSCT was the favorable factor for FFS and HRQoL (P < 0.0001). These results suggest that first-line haplo-HSCT combined with UCB infusion might provide a better chance of success and HRQoL than first-line IST for SAA patients.

Authors+Show Affiliations

National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Institute of Blood and Marrow Transplantation of Soochow University, Suzhou, China.Department of Hematology, The Affiliated Huai'an Hospital of Xuzhou Medical University and The Second People's Hospital of Huai'an, Huai'an, Jiangsu Province, China.Department of Hematology, Xian Yang Central Hospital, Xianyang, Shanxi Province, China.National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Institute of Blood and Marrow Transplantation of Soochow University, Suzhou, China.National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Institute of Blood and Marrow Transplantation of Soochow University, Suzhou, China.National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Institute of Blood and Marrow Transplantation of Soochow University, Suzhou, China.Department of Hematology, The Affiliated Hospital of Nantong University, Nantong, Jiangsu Province, China.Department of Hematology, People Hospital of Xingtai, Xingtai, Hebei Province, China.Department of Hematology, Longyan First Hospital Affiliated to Fujian Medical University, Longyan, Fujian Province, China.Department of Hematology, People Hospital of Xinghua, Xinghua, Jiangsu Province, China.The Second Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu Province, China.Department of Hematology in Haikou Municipal People's Hospital, Affiliated Haikou Hospital Xiangya School of Medicine Central South University, Haikou, Hainan Province, China.Department of Hematology, The Affiliated Hospital of Nantong University, Nantong, Jiangsu Province, China.National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Institute of Blood and Marrow Transplantation of Soochow University, Suzhou, China. mm85124@sina.com.National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Institute of Blood and Marrow Transplantation of Soochow University, Suzhou, China. wudepei@suda.edu.cn.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32591644

Citation

Liu, Limin, et al. "Comparison of Efficacy and Health-related Quality of Life of First-line Haploidentical Hematopoietic Stem Cell Transplantation With Unrelated Cord Blood Infusion and First-line Immunosuppressive Therapy for Acquired Severe Aplastic Anemia." Leukemia, 2020.
Liu L, Zhang Y, Jiao W, et al. Comparison of efficacy and health-related quality of life of first-line haploidentical hematopoietic stem cell transplantation with unrelated cord blood infusion and first-line immunosuppressive therapy for acquired severe aplastic anemia. Leukemia. 2020.
Liu, L., Zhang, Y., Jiao, W., Zhou, H., Wang, Q., Jin, S., Cai, Y., Zhao, L., Shangguan, X., Liu, Z., Xu, J., Lei, M., Yan, X., Miao, M., & Wu, D. (2020). Comparison of efficacy and health-related quality of life of first-line haploidentical hematopoietic stem cell transplantation with unrelated cord blood infusion and first-line immunosuppressive therapy for acquired severe aplastic anemia. Leukemia. https://doi.org/10.1038/s41375-020-0933-7
Liu L, et al. Comparison of Efficacy and Health-related Quality of Life of First-line Haploidentical Hematopoietic Stem Cell Transplantation With Unrelated Cord Blood Infusion and First-line Immunosuppressive Therapy for Acquired Severe Aplastic Anemia. Leukemia. 2020 Jun 26; PubMed PMID: 32591644.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Comparison of efficacy and health-related quality of life of first-line haploidentical hematopoietic stem cell transplantation with unrelated cord blood infusion and first-line immunosuppressive therapy for acquired severe aplastic anemia. AU - Liu,Limin, AU - Zhang,Yanming, AU - Jiao,Wenjing, AU - Zhou,Huifen, AU - Wang,Qingyuan, AU - Jin,Song, AU - Cai,Yifeng, AU - Zhao,Liyun, AU - Shangguan,Xiaohui, AU - Liu,Zefa, AU - Xu,Jinge, AU - Lei,Meiqing, AU - Yan,Xiaoyun, AU - Miao,Miao, AU - Wu,Depei, Y1 - 2020/06/26/ PY - 2020/01/14/received PY - 2020/06/16/accepted PY - 2020/05/06/revised PY - 2020/6/28/entrez JF - Leukemia JO - Leukemia N2 - We retrospectively compared the efficacy and health-related quality of life (HRQoL) of (1) first-line haploidentical hematopoietic stem cell transplantation (haplo-HSCT, n = 146) combined with unrelated cord blood (UCB) infusion and (2) first-line immunosuppressive therapy (IST, n = 219) in acquired severe aplastic anemia (SAA) patients. At 6 months post treatment, 90.30% patients in the haplo-HSCT group and 18.78% patients in the IST group achieved normal blood routine (P < 0.0001). The time required to discontinue red blood cells and platelets transfusion in the IST group were longer than in the haplo-HSCT group (P < 0.0001). The estimated overall survival at 4 years was similar (80.1 ± 3.5% vs. 80.1 ± 3.0%, P = 0.726); the estimated failure-free survival (FFS) at 4 years was 77.8 ± 3.7% in the haplo-HSCT group and 48.0 ± 3.6% in the IST group (P < 0.0001). Patients treated with haplo-HSCT scored significantly better in the HRQoL than treated with IST (P < 0.0001). In the multivariate analysis, first-line haplo-HSCT was the favorable factor for FFS and HRQoL (P < 0.0001). These results suggest that first-line haplo-HSCT combined with UCB infusion might provide a better chance of success and HRQoL than first-line IST for SAA patients. SN - 1476-5551 UR - https://www.unboundmedicine.com/medline/citation/32591644/Comparison_of_efficacy_and_health-related_quality_of_life_of_first-line_haploidentical_hematopoietic_stem_cell_transplantation_with_unrelated_cord_blood_infusion_and_first-line_immunosuppressive_therapy_for_acquired_severe_aplastic_anemia L2 - http://dx.doi.org/10.1038/s41375-020-0933-7 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.